| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/04/2003 | US6514964 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors |
| 02/04/2003 | US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 02/04/2003 | US6514952 For the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration such as rheumatoid arthritis or allergic disorders |
| 02/04/2003 | US6514939 Mutants of atrial natriuretic factor that are protective for stroke |
| 02/04/2003 | US6514935 Methods of treating hypertension |
| 02/04/2003 | US6514934 For treating sexual dysfunctions in males and females |
| 02/04/2003 | US6514745 Oncoprotein protein kinase |
| 02/04/2003 | US6514738 Given amino acid sequence; microtubular depolymerization activity in presence of ATP; can be used in diagnosis and treatment of cancer, neurological and vesicular transport disorders. |
| 02/04/2003 | US6514491 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 02/04/2003 | CA2272927C Dimesylate salts of neuropeptide y ligands |
| 02/04/2003 | CA2271566C Substituted phenyl pyrimidines useful in the treatment of cns disorders |
| 02/04/2003 | CA2178479C Chroman derivatives |
| 02/04/2003 | CA2171953C Modified truncated complement system regulators |
| 02/03/2003 | WO2002016312A2 Novel compounds inhibiting factor xa activity |
| 02/03/2003 | CA2418283A1 Novel compounds inhibiting factor xa activity |
| 01/30/2003 | WO2003008595A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 01/30/2003 | WO2003008576A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression |
| 01/30/2003 | WO2003008574A1 Mutations in ion channels |
| 01/30/2003 | WO2003008560A2 A novel g protein-coupled receptor, gave8 |
| 01/30/2003 | WO2003008548A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 01/30/2003 | WO2003008457A2 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | WO2003008454A2 Glycoprotein vi fusion proteins |
| 01/30/2003 | WO2003008448A2 Novel human proton-gated channels |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008418A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | WO2003008414A1 Chemical compounds |
| 01/30/2003 | WO2003008412A2 Hetero-bicyclic crf antagonists |
| 01/30/2003 | WO2003008411A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008398A1 Aryl substituted thiazolidinones and the use thereof |
| 01/30/2003 | WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 01/30/2003 | WO2003008388A1 I-form crystal of n-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-n'-propylurea and process for producing the same |
| 01/30/2003 | WO2003008387A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 01/30/2003 | WO2003008380A1 Carboxylic acid derivatives |
| 01/30/2003 | WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | WO2003008373A1 Tyrosine hydrazides |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | WO2003008362A1 Novel 3-aryl-2-hydroxy propanol derivatives and a process for their preparation |
| 01/30/2003 | WO2003008010A1 Stents with vitronectin receptor antagonists against restenosis |
| 01/30/2003 | WO2003008005A2 Catheter and implants for the delivery of therapeutic agents to tissues |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007992A1 Remedies for brain ischemic diseases |
| 01/30/2003 | WO2003007990A1 Myosin agonist |
| 01/30/2003 | WO2003007982A1 Sustained release hgf hydrogel preparations |
| 01/30/2003 | WO2003007980A1 Phosphinate-peptide analogues as inhibitors of procollagen-c-proteinase (pcp) for treating fibrotic diseases |
| 01/30/2003 | WO2003007967A1 Medical preparation for parenteral injection |
| 01/30/2003 | WO2003007964A1 Remedial or preventive agent for cardiopathy or aneurysm containing chymase inhibitory compound |
| 01/30/2003 | WO2003007962A1 A combination therapy for the treatment of heart failure |
| 01/30/2003 | WO2003007961A1 Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments |
| 01/30/2003 | WO2003007958A1 Tetrahydroquinoxalines acting as bradykinin antagonists |
| 01/30/2003 | WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | WO2003007950A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | WO2003007947A1 Use of 4-[(4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis |
| 01/30/2003 | WO2003007943A1 Kinase inhibitors and the use thereof |
| 01/30/2003 | WO2003007942A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 01/30/2003 | WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | WO2003007923A2 Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases |
| 01/30/2003 | WO2003007922A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | WO2003007921A2 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007888A2 Fat accumulation-modulating compounds |
| 01/30/2003 | WO2003007872A2 Process for the preparation of citalopram hydrobromide |
| 01/30/2003 | WO2003007840A2 Stent vascular intervention device and method |
| 01/30/2003 | WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002079478A3 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders |
| 01/30/2003 | WO2002070510A3 Amino dicarboxylic acid derivatives with pharmaceutical properties |
| 01/30/2003 | WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 01/30/2003 | WO2002060449A3 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates |
| 01/30/2003 | WO2002055136A3 Intrasvascular drug delivery device and use therefor |
| 01/30/2003 | WO2002051435A3 New therapeutic uses of smr1 peptides |
| 01/30/2003 | WO2002049642A3 Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acids and their esters as agents useful for healing skin lesions and stimulants of angiogenesis |
| 01/30/2003 | WO2002048180A3 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
| 01/30/2003 | WO2002043786A3 Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders |
| 01/30/2003 | WO2002038158A8 Improved treatment |
| 01/30/2003 | WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/30/2003 | WO2002016567A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/30/2003 | WO2002014536A3 Odulating multiple lineage kinase proteins |
| 01/30/2003 | WO2002014356A3 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 01/30/2003 | WO2002005795B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/30/2003 | WO2002004491A3 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001093849A3 Treatment of gastroesophageal reflux disease using piperidine derivatives |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | US20030023990 Jnk3 modulators and methods of use |
| 01/30/2003 | US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc. |
| 01/30/2003 | US20030023098 Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| 01/30/2003 | US20030022940 Novel pharmaceutical formulations of modafinil |
| 01/30/2003 | US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022934 For therapy and prophylaxis of pain and/or neurodegenerative disorders |